Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030
Asia Pacific Breast Cancer Therapeutics Market Forecast to 2030 – Regional Analysis – by Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), and Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Launch of Several Diagnostics and Screening Programs Fuels the Asia Pacific Breast Cancer Therapeutics Market
Advancements in personalized medicine, immunotherapy, combination therapies, drug delivery systems, liquid biopsies, AI, and patient-centric approaches are expected to shape the future of breast cancer treatment. These trends aim to improve treatment outcomes, reduce side effects, and enhance breast cancer patients overall quality of life.
Early disease detection plays a major role in improving patient outcomes and survival rates. Various organizations and healthcare providers are implementing screening programs to detect breast cancer at an initial stage when it is more treatable. The World Health Organization released a new Global Breast Cancer Initiative Framework in February 2013 that serves as a plan for fulfilling the goal of saving 2.5 million people from breast cancer by 2040. To achieve this, the new Framework, unveiled ahead of the World Cancer Day campaign, urges nations to follow the three pillars of health promotion for early detection, prompt diagnosis, and thorough management of breast cancer. These programs often include mammography, clinical breast exams, and self-breast exams to identify any abnormalities or signs of breast cancer. Implementing these programs has increased awareness and early detection of breast cancer cases, resulting in higher demand for effective therapeutics.
In addition, many advancements in diagnostic technologies have been witnessed across the globe. The National Library of Medicine states that early detection and precise diagnosis are essential for enhancing prognosis. Breast cancer assessment frequently makes use of radiographic imaging modalities such as digital mammography (DM), digital breast tomosynthesis (DBT), magnetic resonance imaging (MRI), ultrasound (US), and nuclear medicine procedures. Histopathology (HP) is the gold standard for determining the presence of cancer. Furthermore, using artificial intelligence (AI) technology to depict medical images quantitatively has significant potential for improving breast cancer segmentation, diagnosis, and prognosis. These technologies help healthcare providers identify the extent and characteristics of the tumor, allowing them to develop personalized treatment plans. Thus, the launch of diagnostic and screening programs, coupled with advancements in diagnostic technologies, contributes to the Asia Pacific breast cancer therapeutics market growth.
Asia Pacific Breast Cancer Therapeutics Market Overview
The breast cancer therapeutics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth is attributed to factors including growing burden of breast cancers among women coupled with advancements in personalized medicine, immunotherapy, combination therapies, and drug delivery systems.
The breast cancer therapeutics market in China is projected to witness substantial growth in the coming years, owing to the rising prevalence of breast cancer, increasing aging population, lifestyle changes, and others. China accounted for 24% of cases with new diagnoses and 30% of cancer-related fatalities globally in 2020, as per CDC statistics published on April 14, 2023. Over the last three decades, the age-standardized incidence of breast cancer climbed from 17.07 per 100,000 in 1990 to 35.61 per 100,000 in 2019. Advancements in treatment options have played a crucial role in driving the demand for breast cancer therapeutics in China.
Also, out of 1 in 10 women in Japan will acquire breast cancer at some point. The pink ribbon campaign in October and other initiatives have raised awareness of the disease among Japanese people, including the importance of self-checks and other early detection methods that, when used, increase the survival rate to over 90%. The identification of typical risk variables, however, lags. Thus, the breast cancer therapeutics market in Japan is expected to grow significantly due to an aging population, treatment options, government initiatives and policies, high healthcare expenditure, rising awareness, and technological advancements.
Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Breast Cancer Therapeutics Market Segmentation
The Asia Pacific breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.
Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.
In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.
By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.
Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific breast cancer therapeutics market in 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc are some of the leading companies operating in the Asia Pacific breast cancer therapeutics market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the Asia Pacific breast cancer therapeutics market was valued at US$ 6,986.37 million in 2022 and is expected to reach US$ 15,819.83 million by 2030, registering a CAGR of 10.8% from 2022 to 2030. Increased support from government and private organizations is among the critical factors attributed to the Asia Pacific breast cancer therapeutics market expansion.
Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. In 2021, as part of the Swasth Mahila, Swasth Goa initiative, 100 thousand Goan women in India intended to receive free breast cancer screenings, indicating that 50% of the states age-eligible female population will receive screenings. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.
Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Asia Pacific breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.
On the contrary, high cost of diagnosis and treatment hampers the growth Asia Pacific breast cancer therapeutics market.
Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 63.7% share of the Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 4,450.77 million. It is projected to garner US$ 10,637.22 million by 2030 to expand at 11.5% CAGR during 2022-2030.
In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 67.4% share of the Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 4,712.10 million. It is projected to garner US$ 11,063.48 million by 2030 to expand at 11.3% CAGR during 2022-2030.
By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 75.3% share of Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 5,262.43 million. It is projected to garner US$ 12,176.71 million by 2030 to expand at 11.1% CAGR during 2022-2030.
Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held 24.9% shares of Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 1,742.42 million. It is projected to garner US$ 4,339.68 million by 2030 to expand at 12.1% CAGR during 2022-2030.
Key players operating in the Asia Pacific breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc, among others.
– In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.
– In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Breast Cancer Therapeutics Market – Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market – Asia Pacific Market Analysis
5.1 Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
6. Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Drug Therapy
6.1 Overview
6.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Breast Cancer Type
7.1 Overview
7.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Breast Cancer Therapeutics Market -Country Analysis
9.1 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Asia Pacific Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Asia Pacific Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 China
9.1.3.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Japan
9.1.3.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 India
9.1.3.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Australia
9.1.3.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.5 South Korea
9.1.3.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.6 Rest of Asia Pacific
9.1.3.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation
Table 2. Asia Pacific Breast Cancer Therapeutics Market, by Targeted Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Breast Cancer Therapeutics Market, by Hormonal Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 4. China Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 5. China Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 6. China Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 7. China Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. China Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. Japan Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. India Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 15. India Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 16. India Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 17. India Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. India Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 24. South Korea Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Breast Cancer Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Breast Cancer Therapeutics Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market
LIST OF FIGURES
Figure 1. Asia Pacific Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Asia Pacific Breast Cancer Therapeutics Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Asia Pacific Breast Cancer Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Breast Cancer Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market
The List of Companies – Asia Pacific Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.